The Hike Is Priced In.
The Guidance Isn't.
Week of September 15 · GOOGL · HCA · LITE
This morning's CPI pushed the odds of a Wednesday rate hike to roughly 90%. At those odds the hike itself is old news. What moves your account is the sentence that comes after it.
Seasonality Finds the Window. Option Insanity Finds the Trade.
This watchlist answers one question extremely well: when has the calendar been on your side? That is a powerful filter — and it is only ever half of the job. The other half is what you actually put on once you are there.
Option Insanity comes at the market from a completely different angle. It is the SmartTrading team's option-scan work, and it is open to you now — a second lens for traders who would rather not run on one signal alone.
Everything you need — what it looks for, how it works and how to get access — is on the page.
See Option Insanity48% to 90% in one month
August CPI arrived Friday at +0.4% for the month and 3.4% year-over-year, both matching the Dow Jones consensus. Core rose 0.3% — a tenth hotter than expected — with the twelve-month core at 2.4%. Both readings remain comfortably above the Fed's 2% target, and odds of a Wednesday hike promptly climbed to around 90%.
The path here was brutal for anyone positioned the other way. A month ago the odds sat near 48%. Then came a blowout September 4 jobs report with August payrolls at 162,000, a hotter-than-expected PPI on Thursday that pushed odds past 73%, and rising oil prices tied to Middle East supply disruption. Treasury yields are holding near multiyear highs after a sharp bond selloff. Warsh told Jackson Hole that returning inflation to target was his primary focus. The market has finally taken him at his word.
Here is the part most coverage will get wrong next week. At 90% odds, a quarter-point hike is already in the price. Buying or selling on the decision itself is trading a headline everyone has read. The real event on Wednesday is the guidance — whether the committee signals one-and-done, or opens the door to December.
Which is why this week's three names were chosen to sit on different sides of that answer. A mega-cap with a fortress balance sheet, the cheapest defensive name on the board, and the highest-beta AI play we could find. One question, three different exposures to it.
The giant on sale
GOOGL takes two of the four columns: the highest frequency on the list at 89.47% and the highest annualized return at +91.97%, with a healthy 10.45 profit factor and a 76.19% win rate. No weak spot anywhere in the row.
Here is why that matters right now. Alphabet has slid roughly 10% over the past thirty days, from about $372 down to the mid-$330s. It is sitting essentially on its 200-day moving average near $340 and below its 50-day near $347. The 52-week range runs from $225 to $404. This is not a broken chart. It is a mega-cap that has quietly handed back a quarter of its year.
The business behind it did not shrink. Quarterly revenue came in around $119.8 billion at a gross margin near 81.5% — the search and cloud engines are still throwing off enormous cash. Gemini has been shipping fast, with the 3.8 Flash model and a cybersecurity variant aimed at government and enterprise, plus Gemini Robotics ER 2 on the physical-AI side.
On September 3 a federal judge rejected the Department of Justice's request that Google divest AdX, its ad exchange. That removes one of the two structural threats that has hung over the stock, and it follows the earlier ruling that let Google keep Chrome and Android. The single biggest overhang on this name keeps resolving in its favour.
The FTC is reportedly in the final stages of a YouTube investigation over consumer-protection issues, with a lawsuit said to be in preparation. Google has already settled with the UK over Play Store practices for about $353 million and is rewriting European policy to avoid antitrust fines. Separately, 2026 capex guidance of $175–$185 billion more than doubles last year — Barclays has flagged that infrastructure and Waymo costs will weigh on profitability all year.
GOOGL is the highest-quality setup on this week's list and the numbers agree: best frequency, best annualized return, no weak column. It is on offer because of a 10% drawdown and a legal docket that keeps generating headlines — even as the biggest of those headlines just broke its way. Watch the capex line, not the lawsuits.
The one that wins most often
HCA is the metronome. An 85.71% annual win rate is the highest figure on this list and the highest we have printed in some time. The trade-off sits in the profit factor: 5.47, the lowest of the three. Wins often, wins modestly.
That is exactly the personality you would expect from the largest hospital operator in the United States. Demand for emergency rooms and surgical suites does not care much about the business cycle, and the Q2 numbers showed it: revenue of roughly $20.23 billion against a $19.39 billion consensus, net income near $1.70 billion or $7.62 per diluted share, adjusted EBITDA around $4.03 billion, with same-facility admissions up 2.5%.
And yet the stock is down roughly 13% year to date, trading near $405 against a 52-week range of $354 to $557. It changes hands at a P/E near 13.6 with a PEG around 1.33 — and on Simply Wall St's fair-multiple framework, a business with HCA's margins and scale would screen closer to 26.7x. Cantor Fitzgerald has an Overweight rating and a $525 target on it.
HCA declared a $0.78 quarterly dividend payable September 30, with the record date falling Wednesday, September 16 — the same day the Fed announces. If you want the payment, the calendar is specific and it is next week.
In July, HCA cut its 2026 EPS guidance to $28.70–$30.50 from $29.10–$31.50, blaming a worsening payer mix as patients lost coverage on the health-insurance exchanges — an estimated $400 million hit to pre-tax income in a single quarter. The stock fell around 10% premarket and logged five straight down days. There is also a securities-fraud investigation from Pomerantz circling, and union activity that could pressure staffing costs. Forecast earnings growth of about 4.6% a year trails the broader market badly.
HCA offers the best win rate on this list attached to the cheapest valuation — a defensive, admissions-driven business at 13.6x earnings with a $525 Overweight target and a dividend record date inside the window. The reason it is cheap is real: a guidance cut driven by patients losing insurance, a fraud investigation, and growth that trails the market. Highest hit rate, smallest swing.
The rocket that already launched
LITE's row is the most balanced of the three and leads none of it: an 80% frequency (lowest here), an 8.8 profit factor, a +79.42% annualized return and an 80% win rate. Solid everywhere, spectacular nowhere — which is a strange thing to say about a stock that is up 122% year to date.
Lumentum makes the optical and photonic components that move data inside AI data centres — lasers, transceivers, the physical layer that is rapidly replacing copper as interconnect distances and speeds outgrow what wire can carry. It joined the S&P 500 this year, and August's fiscal Q4 print beat with an upbeat forecast.
Then Tuesday happened. The stock jumped about 11% on September 8 as Deutsche Bank initiated at Buy with a $1,200 target, calling Lumentum's III-V laser technology critical across every future optical architecture, and Evercore ISI started it at Outperform with $1,100. Citi went to $1,200. Management lifted long-term guidance and floated roughly $40 of earnings power by fiscal 2028. Street targets now cluster near $1,140.
Deutsche Bank named Lumentum and Coherent its highest-conviction picks among hardware names in the AI era — the thesis being that Lumentum wins whether the industry lands on pluggable optics or co-packaged optics. The connectivity bottleneck is the trade.
Three things. One: LITE trades near $931 while independent fair-value work sits closer to $863 — below the price, having been cut from $802 and revised repeatedly as the stock outran the models. Two: the P/E is negative; this is not yet a GAAP-profitable company. Three: the company president sold 1,500 shares at an average $912.33 — roughly $1.4 million — and BofA sits at Neutral with a $1,000 target it recently lowered. Washington is also scrutinising Chinese-supplied optical transceivers in US data centres, which cuts both ways for the supply chain.
LITE is the cleanest pure play on the AI connectivity bottleneck, with two fresh initiations at $1,100–$1,200 and a credible path to $40 of earnings power. It also has the weakest frequency on this list, a negative P/E, insider selling, and a price already above some fair-value estimates after a 122% year. Great business, late entry — size it for the gap between those two facts.
The three, side by side
| Ticker | Frequency | Profit Factor | Ann. Return | Annual Win % | Personality |
|---|---|---|---|---|---|
| GOOGLAlphabet | 89.47% | 10.45 | +91.97% | 76.19% | Quality, on a 10% pullback |
| HCAHCA Healthcare | 84.62% | 5.47 | +77.54% | 85.71% | Wins most often, wins small |
| LITELumentum | 80% | 8.8 | +79.42% | 80% | Highest beta, latest entry |
Wednesday will be loud. Your decisions were made on Friday.
There is a specific kind of stress that comes from making a trading decision while the news is breaking. Super Seasonal exists to move that decision earlier — to a quiet moment, with the full statistical profile in front of you, before anyone is shouting.
The goal was never to trade more. It was to trade fewer, better-prepared ideas — and to spend Wednesday watching the Fed instead of scrambling because of it.
Sign Up to View Full Trade DetailsThe Big Picture
One decision on Wednesday, three very different ways to be exposed to it.
Notice the ladder. HCA wins most often and moves least. LITE moves most and wins least often. GOOGL sits in between and leads three of four columns. If Wednesday's guidance is hawkish, the long-duration AI name takes the hardest hit and the hospital operator barely notices. If it reads one-and-done, that ordering flips. You are not being asked to guess which — you are being handed three different answers so the week is not a single bet.
And one honest note on entries. GOOGL is down 10% in a month. HCA is down 13% on the year. LITE is up 122% and jumped 11% on Tuesday. Two of these are discounts and one is a chase. The statistics do not distinguish between those — but your position sizing should.
Sign Up to View Full Trade DetailsSuper Seasonal Trade Desk
One Signal Is a Guess. Two Is a Case.
Next week the Fed moves, and every open position in the market gets re-priced on one sentence of guidance. Weeks like that are exactly when a single point of view starts to feel thin.
Option Insanity is the SmartTrading team's option-scan work — built to sit alongside what you already do, not replace it. If this week's setups gave you the when, this is where you go for a second read on the what.
See Option InsanityOptions involve risk and are not suitable for every investor. Nothing here is personalized financial advice; see the product page for full details and terms.
